Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients

Summary

To evaluate the efficacy of metformin as an adjunct therapy in improving depressive symptoms and metabolic markers in newly diagnosed obese depressed patients on standard antidepressant therapy. investigator will compare between Two groups 1\. metformin group 2 placebo group Primary outcome measure will be the improvement in depressive symptoms, indicating by a reduction in Hamilton Depression Rating Scale (HAM-D) scores. Secondary outcome measures will include the assessment of oxidative stress markers, specifically by measuring the increase in enzymatic activity of superoxide dismutase, catalase, and glutathione peroxidase Investigators hypothesize that the addition of metformin to standard antidepressant treatment will result in a significant reduction in symptoms of depression among newly diagnosed obese individuals.

Eligibility

Inclusion Criteria:

* • Age \>18 to \<45 years

  * Gender: Both genders (Male and Female)
  * BMI \>25
  * Diagnosis: Newly diagnose cases of depression (mild to severe)
  * HBA1C: Less than 5.7% (non-diabetic range)

Exclusion Criteria:

* Existing diabetes

  * Acute illnesses like acute kidney injury, recent history of myocardial infarction, acute liver injury
  * Intellectual disabilities or inability to understand due to any reason
  * Presence of Psychiatric disorders other than depression
  * Chronic kidney disease (eGFR \< 45 mL/min/1.73 m²).
  * Use of any psychotropic medication within the past 6 months.

Conditions1

Interventions1

Related trials

• Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia — Cairo University
• Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations — Instituto Nacional de Cancerologia de Mexico
• Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse — Istituto Ortopedico Rizzoli
• Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes — Anna Stanhewicz, PhD
• Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function — University of Kansas Medical Center

Browse More Trials